What is gas chromatography (GC) and how is it used in pharmaceutical analysis?
Gas chromatography (GC) is a separation technique that uses a carrier gas (helium, hydrogen, or nitrogen) to transport volatile sample components through a column containing a stationary phase; the components separate based on their differential affinity for the stationary phase (partition between the gas phase and the liquid stationary phase); each component travels through the column at a characteristic rate determined by its vapour pressure and its interaction with the stationary phase; components exit the column sequentially and are detected by the detector, producing a chromatogram (plot of detector signal vs. time); the retention time (time for a component to travel through the column) identifies the compound and the peak area quantifies it. Key pharmaceutical applications: residual solvent analysis (ICH Q3C/USP <467>) – GC is the primary technique for detecting and quantifying volatile organic solvents used in pharmaceutical synthesis that may remain in the final API or drug product; headspace GC (HS-GC) is the preferred technique, where the pharmaceutical sample is equilibrated at elevated temperature and the headspace gas is injected into the GC column; class 1 solvents (benzene, carbon tetrachloride, 1,2-dichloroethane) are carcinogens with PDEs of 0.05-2 mg/day and require the highest sensitivity detection (GC-MS); class 2 solvents (acetonitrile, methanol, toluene) require lower LOD; class 3 solvents (acetone, ethanol, IPA) have high PDEs and are monitored primarily for GMP reasons. Gas purity verification – headspace GC can verify the purity of gases used in pharmaceutical processes. Tablet coating analysis – GC can analyse residual solvents in film coatings.
What is ICP-MS and how does it differ from ICP-OES and AAS?
All three techniques (ICP-MS, ICP-OES, AAS) are used for elemental analysis in liquid samples but differ in detection principle, sensitivity, and analytical capabilities: AAS (Atomic Absorption Spectrometry): measures the absorption of light at a characteristic wavelength by ground-state atoms; each element requires a separate hollow cathode lamp; single-element measurement at a time; moderate sensitivity (ppm to ppb level); graphite furnace AAS (GFAAS) provides ppb to ppt sensitivity for single elements; lower throughput than ICP; advantages: simpler operation, lower cost, well-established pharmaceutical methods. ICP-OES (Inductively Coupled Plasma Optical Emission Spectrometry): the plasma (6,000-8,000 K argon plasma) excites atoms to emit light at characteristic wavelengths; simultaneous multi-element analysis (20-70 elements in 1-3 minutes); sensitivity: ppm to low ppb level (10-100 µg/L); adequate for ICH Q3D elements with higher PDEs (iron, manganese); not sensitive enough for mercury, arsenic at parenteral PDE levels. ICP-MS (Inductively Coupled Plasma Mass Spectrometry): the plasma ionises atoms; the mass spectrometer sorts and counts ions by mass-to-charge ratio; most sensitive elemental analysis technique (sub-ppb to ppt); simultaneous 70+ element analysis in one run; required for ICH Q3D elements with very low oral and parenteral PDEs (mercury 1-30 µg/day, arsenic 0.5-15 µg/day); highest cost; most complex operation. Selection for ICH Q3D: ICP-OES is adequate for class 3 elements (oral products) where sensitivity is less critical; ICP-MS is required for class 1 elements (As, Cd, Hg, Pb) and parenteral products where the allowed levels approach or below 0.1 ppb in the sample as prepared.
What is DSC and how is it used for pharmaceutical polymorphism?
DSC (Differential Scanning Calorimetry) measures the difference in heat flow between a sample and an inert reference as both are heated or cooled at a controlled rate; when the sample undergoes a thermal transition (melting, crystallisation, glass transition, polymorphic conversion, decomposition), it absorbs or releases heat differently from the reference, producing a characteristic peak or step in the DSC signal. Polymorphism in pharmaceuticals: a pharmaceutical compound can exist in multiple crystal structures (polymorphs) or in amorphous form; different polymorphs of the same compound have different physical properties – different melting points, different solubility, different dissolution rates, and potentially different bioavailability; the most stable polymorph at the intended storage condition must be used in the commercial drug product to ensure reproducible performance throughout shelf life; the FDA/CDSCO requires complete polymorphic characterisation of APIs and demonstration that the commercial process consistently produces the correct polymorph. DSC identification of polymorphs: each polymorph has a characteristic melting temperature (Tm) and heat of fusion (ÎHfus); different polymorphs of the same compound appear as separate melting peaks in the DSC at different temperatures; example: carbamazepine has four polymorphs with melting temperatures of approximately 189, 177, 174, and 167 degrees C – DSC clearly distinguishes them; the amorphous form shows a glass transition (Tg) rather than a sharp melting peak. DSC limitations for polymorphism: if two polymorphs have very similar melting temperatures (within 2-5 degrees C), DSC may not resolve them; combined use with XRPD (X-ray Powder Diffraction) and solid-state NMR provides the most complete polymorphic characterisation.
What is XRF and what are its capabilities and limitations?
XRF (X-Ray Fluorescence) is a non-destructive elemental analysis technique based on the emission of characteristic secondary X-rays from a material that has been excited by bombarding it with high-energy primary X-rays. Mechanism: primary X-rays from an X-ray tube eject inner-shell electrons from atoms in the sample (photoionisation); outer-shell electrons fall to fill the vacancies, releasing energy as secondary (fluorescent) X-rays at characteristic energies specific to each element; a detector measures the energy (EDXRF) or wavelength (WDXRF) and intensity of the secondary X-rays; each element has unique characteristic X-ray energies enabling identification; intensity is proportional to concentration enabling quantification. Capabilities: simultaneous multi-element analysis from sodium (Na, Z=11) to uranium (U, Z=92); non-destructive (sample is not altered by the measurement); no sample preparation for solids (measure directly as received); bulk elemental analysis; concentration range from ppm to 100%; applicable to metals, alloys, rocks, minerals, cements, soils, polymer films, coatings. Limitations: limited surface sensitivity (analyser measures a thin layer from 3 µm to 1 mm depth depending on element, matrix, and X-ray energy – light elements measured shallower, heavy elements deeper); cannot distinguish oxidation states (measures total chromium, not Cr(VI) vs. Cr(III)); cannot detect elements lighter than sodium (carbon, hydrogen, nitrogen, oxygen not detectable by standard XRF); quantitative accuracy depends on matrix-matched calibration (calibration standards must have similar matrix to unknowns); interference between adjacent elements with overlapping X-ray peaks. Indian industrial applications: steel mill alloy composition verification (Fe, Mn, Cr, Ni, Mo, V composition in carbon steels, stainless steels, tool steels); cement quality control (SiO2, Al2O3, Fe2O3, CaO, MgO, SO3); mining exploration and ore grade (iron ore, bauxite, copper ore grade estimation); RoHS screening in electronics manufacturing (Pb, Cd, Hg, Cr, Br in plastic components, PCBs, solder).
What is particle size analysis and which method should be used?
Particle size analysis characterises the size distribution of particles in a powder, suspension, or emulsion; different techniques are suited to different particle size ranges and sample types. Laser diffraction (ISO 13320): measures the angular distribution of laser light scattered by particles; size range 0.1-3,500 µm; high sample throughput; suitable for pharmaceutical powders, pigments, cement, food particles; wet (liquid dispersion) or dry (air dispersion) sample introduction; provides volume-weighted particle size distribution (D10, D50, D90 percentiles); standard method for pharmaceutical API and excipient particle size in BP, USP, and JP. Dynamic light scattering (DLS, also called PCS or QELS): measures the Brownian motion of particles in liquid suspension through time-correlation analysis of scattered light intensity fluctuations; size range 1 nm to 10 µm; best for nanoparticles (liposomes, colloidal drug carriers, protein aggregates, polymer nanoparticles); provides intensity-weighted hydrodynamic diameter (Z-average); cannot handle polydisperse samples well (broad size distributions appear as a single average rather than a meaningful distribution). Nanoparticle tracking analysis (NTA): tracks individual nanoparticles in liquid suspension using a microscope and laser; measures each particle's Brownian motion; provides number-weighted size distribution; better for polydisperse nanoparticle samples than DLS; size range 10-2,000 nm. Sieve analysis: mechanical separation through a series of sieves of decreasing aperture; simple; low cost; well-established (IS 460 standards for sieve dimensions); limited to particles above 32 µm; provides cumulative mass fraction in each sieve fraction; standard for agricultural products, construction materials, and coarse pharmaceutical excipients. Microscopy (optical or electron): measures individual particle dimensions directly; time-consuming; provides particle shape information; used for validation of other methods and for non-spherical particles where equivalent sphere models are inadequate.
